title: Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders.
abstract: This 12-week drug-monitoring study was conducted to evaluate the efficacy of Sanhelios Mussel Lyprinol Lipid Complex on 50 adult men and women with inflammatory rheumatoid arthritis. A total of 34 patients required drug therapy before and during the study. By the end of the study, 21 (62%) patients were able to reduce their dosage and 13 were able to terminate drug therapy. At the end of the treatment period, 38% were regarded symptom free, and the number of patients with severe pain decreased significantly from 60% at baseline to 25% at the completion of the trial. A significant effect was observed for each investigated parameter. The special combination of Lyprinol and omega-3 fatty acids was generally very well tolerated, with only one, nonserious adverse event (mild nausea) reported. This dietary supplement may therefore be considered an effective and well-tolerated component of treatment regimens for inflammatory rheumatoid arthritis.
authors.affiliation: PhytoPharm Consulting, Institute for Phytopharmaceuticals, Berlin, Germany.
authors.forename: Joerg
authors.initials: J
authors.lastname: Gruenwald
authors.forename: Hans-Joachim
authors.initials: HJ
authors.lastname: Graubaum
authors.forename: Knuth
authors.initials: K
authors.lastname: Hansen
authors.forename: Barbara
authors.initials: B
authors.lastname: Grube
mesh_terms: D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008055:Lipids / Q000008:administration & dosage*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D010147:Pain Measurement; D011446:Prospective Studies; D011753:Pyrones / Q000008:administration & dosage*; D016059:Range of Motion, Articular / Q000187:drug effects / Q000502:physiology; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D008055:Lipids; D011753:Pyrones; C418997:lyprinol; C027493:dehydroacetic acid; D015118:Eicosapentaenoic Acid